Want to see PRME full AI Analyst Report?
Prime Medicine, Inc. (PRME) Stock Forecast & Price Target
936 Followers
PRME Analyst Ratings
Strong Buy
7Buy1Hold0Sell
Based on 8 analysts giving stock ratings to Prime Medicine, Inc. in the past 3 months
PRME Stock 12 Month Forecast
Average Price Target
$7.67▲(54.26% Upside)Based on 8 Wall Street analysts offering 12 month price targets for Prime Medicine, Inc. in the last 3 months. The average price target is $7.67 with a high forecast of $11.00 and a low forecast of $5.00. The average price target represents a 54.26% change from the last price of $4.97.
Past 12 Months12 Month ForecastJan2026Oct2026
High$11.00
Average$7.67
Low$5.00
Highest Price TargetHighest$11.00Average Price Target$7.67Lowest Price TargetLowest$5.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Cory Jubinville, PhD | LifeSci Capital | $6 | buy | 20.72%Upside | Reiterated | 10/05/26 | ||
| Arthur He CFA | H.C. Wainwright | $8 | buy | 60.97%Upside | Reiterated | 10/01/26 | ||
| Kostas Biliouris | Oppenheimer | $11 | buy | 121.33%Upside | Reiterated | 09/25/26 | ||
| Keay Nakae | Chardan Capital | $7 | buy | 40.85%Upside | Reiterated | 09/24/26 | ||
| Joseph Thome | TD Cowen | ― | buy | ― | Reiterated | 09/24/26 | ||
| David Lebowitz | BMO Capital | $9 | buy | 81.09%Upside | Reiterated | 09/24/26 | ||
| Terence Flynn | Morgan Stanley | ― | hold | ― | Assigned | 08/10/26 | ||
| Boris Peaker | JonesTrading | $5 | buy | 0.60%Upside | Reiterated | 08/06/26 | ||
 Unknown AnalystNot Ranked | Wedbush | $8 | buy | 60.97%Upside | Reiterated | 06/22/26 | ||
| Tessa Romero | J.P. Morgan | ― | hold | ― | Reiterated | 11/18/25 | ||
| Samantha Semenkow | Citi | $5→$4.25 | hold | -14.49%Downside | Reiterated | 11/11/25 |
| Rating | Follow | Article | |||
|---|---|---|---|---|---|
| Cory Jubinville, PhDLifeSci Capital | BuyReiterated$6 | 10/05/26 | 20.72%Upside | ||
| Arthur He CFAH.C. Wainwright | BuyReiterated$8 | 10/01/26 | 60.97%Upside | ||
| Kostas BiliourisOppenheimer | BuyReiterated$11 | 09/25/26 | 121.33%Upside | ||
| Keay NakaeChardan Capital | BuyReiterated$7 | 09/24/26 | 40.85%Upside | ||
| Joseph ThomeTD Cowen | BuyReiterated | 09/24/26 | ― | ||
| David LebowitzBMO Capital | BuyReiterated$9 | 09/24/26 | 81.09%Upside | ||
| Terence FlynnMorgan Stanley | HoldAssigned | 08/10/26 | ― | ||
| Boris PeakerJonesTrading | BuyReiterated$5 | 08/06/26 | 0.60%Upside | ||
| Unknown AnalystWedbushNot Ranked | BuyReiterated$8 | 06/22/26 | 60.97%Upside | ||
| Tessa RomeroJ.P. Morgan | HoldReiterated | 11/18/25 | ― | ||
| Samantha SemenkowCiti | HoldReiterated$5→$4.25 | 11/11/25 | -14.49%Downside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Prime Medicine, Inc.
3 Months
Success Rate3/9 ratings generated profit
33%
Average Return
+8.03%
Copying Cory Jubinville, PhD's trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of +8.03% per trade.
1 Year
Success Rate7/9 ratings generated profit
78%
Average Return
+29.57%
Copying Cory Jubinville, PhD's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +29.57% per trade.
2 Years
Success Rate7/9 ratings generated profit
78%
Average Return
+29.57%
Copying Cory Jubinville, PhD's trades and holding each position for 2 Years would result in 77.78% of your transactions generating a profit, with an average return of +29.57% per trade.
PRME Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 13 | 14 | 14 | 12 | 6 |
| Buy | 2 | 1 | 2 | 1 | 1 |
| Hold | 4 | 3 | 2 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 19 | 18 | 18 | 14 | 7 |
In the current month, PRME has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. PRME average Analyst price target in the past 3 months is 7.67.
PRME Financial Forecast
Consensus$0.00
PRME Sales Forecast
Next quarter’s sales forecast for PRME is $0 with a range of ― to ―. The previous quarter’s sales results were $1.15M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
PRME Stock Forecast FAQ
What is PRME’s average 12-month price target, according to analysts?
Based on analyst ratings, Prime Medicine, Inc.’s 12-month average price target is $7.67.
What is PRME’s upside potential, based on the analysts’ average price target?
Prime Medicine, Inc. has 54.26% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PRME a Buy, Sell or Hold?
Prime Medicine, Inc. has a consensus rating of Strong Buy which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.
What is Prime Medicine, Inc.’s price target?
The average price target for Prime Medicine, Inc. is $7.67. This is based on 8 12-month price targets, issued in the past 3 months. The highest analyst price target is $11.00, the lowest forecast is $5.00. The average price target represents a 54.26% increase from the current price of $4.97.
What do analysts say about Prime Medicine, Inc.?
Prime Medicine, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Street analysts.
How can I buy shares of PRME?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
